Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
McKinsey
Dow
McKesson
Colorcon

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Litigation Details for Smithkline Beecham v. Apotex Corp (N.D. Ill. )

See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in Smithkline Beecham v. Apotex Corp
The small molecule drugs covered by the patent cited in this case are   Start Trial and   Start Trial .

Details for Smithkline Beecham v. Apotex Corp (N.D. Ill. )

Date Filed Document No. Description Snippet Link To Document
2000-07-13 134 States Patent and Trademark Office granted Beecham Patent No. 4,721,723 ("the ‘723 Patent“), for …SmithKline’s patent to produce and market their paroxetine. Thus, Sherman was aware of the ‘723 patent and that…collectively "SmithKline") filed a one-count patent infringement complaint against Defendants Apotex…Hemihydrate. " Beecham eventually assigned the patent to SmithKline, which markets the paroxetine as …ii), and advised SmithKline that unlike the ‘723 Patent which is in hemihydrate form, because TorPharm’ External link to document
2000-09-12 143 Beecham obtained United States Patent lt'\@> No. 4,721,723 on the drug Crystalline Paroxetine…to communications with foreign patent agents related to foreign patent activities if the privilege would…functionalism approach to the foreign patent agent problem. Because the patent agents in question were from the…to the foreign patent agent question;(2) the British law extending privilege to patent agent communications…between attorneys and foreign patent agents are unprivileged because patent agents are not attorneys,.. External link to document
2000-09-12 144 Defendants”). Beecham obtained United States Patent lle No. 4,721,723 on the drug Crystalline Paroxetine Hydrochloride…anticipation of patent litigation Judge Bobrick deemed confidential communications with UK patent agents privileged…part Plaintiffs’ objections BACKGROUND This is a patent infringement action brought by Plaintiffs SmithKline…that its product did not infringe on Plaintiffs’ patent because it contained paroxetine in an anhydrous…from the plaintiffs’ United Kingdom [attorney or patent agent].” On the other hand, Judge Bobricl< granted External link to document
2002-07-16 279 of invalidation of U.S. Letters Patent No. 4,721,723 (“_the ‘723 patent”) by public use. The motion encompasses…granted SmithKline summary judgment that the ‘723 patent Was not invalid because of public use, obviating…around TorPharrn’s efforts to invalidate the ‘723 patent under 35' U.S.C. § 112. Although TorPharm casts…specifically enumerated in the language of the ‘ 723 patent to show the presence of infringing material within…that they focus on actual infringement or other patent-related issues, not the hypothetical scenario created External link to document
2003-03-03 351 pat- ent 4,721,723, or “723” as the parties refer to it, after its last three digits. The patent is on an…expiration of drug patents (the patent term for all utility patents, including therefore drug patents, was then…statutory term of the patent. In the case of patent 723 for example, the patent at issue in this case,…SmithKline to be infringed), was patented in patent 728 in 1988, the patent application having been filed…was invented and indeed patented in patent 196 and therefore could not be patented later, SmithKline effectively External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Colorcon
Boehringer Ingelheim
AstraZeneca
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.